Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium
GROTON, Conn.–(BUSINESS WIRE)–Astrocyte Pharmaceuticals Inc., a privately-held drug discovery and development company advancing novel cerebroprotective therapies for patients with brain injury, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing Phase 1 clinical study. Theodore Liston, Ph.D., Vice President of Research at Astrocyte, presented recent findings in an oral session at the U.S. Department of Defense’s premier scientific meeting, the Military Health System Research Symposium (MHSRS) held in Orlando, Florida.
In today’s presentation, Dr. Liston discussed the company’s progress with the first-in-human study (designated AST-004-1-02), promising preclinical efficacy of AST-004 in stroke and traumatic brain injury (TBI), and progress with additional product formulations.
“Our first single-dose Phase 1 clinical study is proceeding as planned and we have now completed all dose levels in healthy volunteers. AST-004 was extremely well tolerated at all dose levels, and there were no significant safety signals or adverse effects associated with AST-004,” said Dr. Liston. “Astrocyte will then conduct an additional Phase 1 study to assess target cerebrospinal concentrations of the drug to confirm doses for use in Phase 2 efficacy studies, the first of which is expected to begin in late 2023 or 1H 2024.”
“The TBI is an absolute health priority for the army; 22% of all combat casualties in recent years are brain damage,” remarked retired Col. Dallas Hack, MD, MPH and Astrocyte advisor. “The data presented by Dr. Liston to military health officials today demonstrates a very encouraging safety, efficacy and pharmaceutical profile for AST-004, and the exciting potential for it to be the much-needed treatment for combatants and civilians with traumatic brain injury.”
About Astrocyte Pharmaceuticals Inc.
Astrocyt Pharmaceuticals Inc. is a privately held, clinical-stage drug discovery and development company dedicated to accelerating the recovery and well-being of brain-injured patients. The company is committed to proving the cerebroprotective benefits of improving astrocyte function and advancing breakthrough therapeutic agents for the treatment of brain damage resulting from stroke, traumatic brain injury, traumatic brain injury, concussion and neurodegenerative disorders such as Alzheimer’s disease. For more information, visit Astrocyte Pharmaceuticals Inc.
The research described in this press release is funded in part by the Medical Technology Enterprise Consortium (MTEC) in cooperation with the US Army Medical Research and Development Command (USAMRDC) of the United States Department of Defense. The views expressed in this article are those of the author and may not reflect the official policy or position of MTEC, the Department of the Army, the Department of Defense, or the United States Government.
This press release contains certain forward-looking statements regarding, among other things, statements relating to the company’s objectives, plans and projections regarding the financial condition, results of operations, market position, product development and business strategy. . These forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, deflect or modify any of them, and could cause actual results to differ materially from current expectations. . No forward-looking statement can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and the company undertakes no obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. except as required by law. .